Ligand(LGND) - 2023 Q3 - Earnings Call Transcript
Ligand(LGND)2023-11-09 03:22
Simon Latimer Moving to slide 4. we will discuss business development and the investment team scale up. One of our key priorities over the last 12 months has been to scale our investment capabilities, including origination, diligence and deal making, to bring more institutional process to the way we originate, negotiate and execute on investments. This requires the best available talent in pharmaceutical investing and deal making. Simon Latimer - Head-Investor Relations Todd Davis - Chief Executive Officer ...